Retinal Vascular Disease
Annexin Pharmaceuticals AB (publ) is involved in clinical research focused on retinal vascular disorders, with attention to conditions that affect the blood vessels of the eye and can impair vision.
- Diabetic Retinopathy
- Retinal Vein Occlusion
The sponsor’s research activity in this area centers on ophthalmic disease states associated with retinal circulation and visual dysfunction.
Ophthalmology
The company’s clinical interest extends to eye disease and vision-threatening retinal conditions, reflecting a therapeutic focus within ophthalmology.
- Retinal pathology
- Visual impairment
Its funded research addresses disorders where retinal damage and vascular compromise are central clinical concerns.
Recombinant Protein Therapeutics
Annexin Pharmaceuticals AB (publ) supports research involving recombinant human Annexin A5, placing emphasis on biologic approaches relevant to ocular disease.
- Annexin A5
- Biologic therapy
This area links the sponsor’s clinical work to targeted therapeutic development for retinal disorders.
Circulatory and Vascular Biology
The sponsor’s research interests include vascular mechanisms relevant to retinal disease, particularly conditions involving disrupted blood flow and vessel injury.
- Microvascular dysfunction
- Retinal ischemia
These themes are directly connected to the clinical profile of retinal disorders studied by the company.
